BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD
Completed
- Conditions
- Wet Macular Degeneration
- Interventions
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 593
- Registration Number
- NCT02279537
Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2251
- Registration Number
- NCT02262676
Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: BAY14-2222_Kogenate-FS FVIII
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 181
- Registration Number
- NCT02263066
Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT02262663
Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization
Completed
- Conditions
- Choroidal Neovascularization
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 353
- Registration Number
- NCT02260687
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Drug: Radium-223 dichloride (Xofigo, BAY88-8223)Drug: Placebo (saline)Drug: ExemestaneDrug: Everolimus
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 283
- Registration Number
- NCT02258451
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Neoplasms
- Interventions
- Drug: Radium-223 dichloride (Xofigo, BAY88-8223)Drug: Placebo (saline)Other: Background hormonal therapy
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99
- Registration Number
- NCT02258464
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Phase 1
Completed
- Conditions
- Medical Oncology
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT02253420
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Completed
- Conditions
- Multiple Sclerosis, Relapsing Remitting
- Interventions
- Drug: Interferon beta-1b (Betaferon®, BAY 86-5046)Device: BETACONNECT
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 498
- Registration Number
- NCT02247310
Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients
Phase 2
Terminated
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: STW5-II (Iberogast N, BAY98-7410)Drug: Placebo
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3
- Registration Number
- NCT02246686
© Copyright 2025. All Rights Reserved by MedPath